Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01B
2023-507179-23-00Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of pembrolizumab, favezelimab and vibostolimab in classical Hodgkin lymphoma (cHL), melanoma and Nonhematologic neoplasms (2 arms), sponsored by Merck & Co. Primary endpoints: Part 1: Area Under the Curve (AUC), Part 1: Maximum Concentration (Cmax) and 6 more. Planned start Apr 2024; status: withdrawn.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)melanomaNonhematologic neoplasms
Beyond the preview
Go deeper on 2023-507179-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507179-23-00.